Curie.Bio: Empowering Biotech Founders With a Revolutionary VC Model
Curie.Bio aims to make it easier for founders of biotech companies by providing them with the facilities and resources needed to develop new drugs. It offers not only funding, but also a team of experts in drug development and R&D services. This allows founders to focus fully on the science without having to deal with the infrastructure.
Curie.Bio's team consists of 80 experts who have collaborated on the development of more than 150 drugs in clinical phase and 30 approved products. They help founders with therapeutic target selection, planning, experiments or competitor analysis. They support startups focused on both platform-based and asset-centric models.
George Voren, PhD is Vice President of Strategy and Operations at Curie.Bio and has experience in academia, biotech and venture capital. He has a PhD in neuroscience and was involved in the development of AZD4041, which is now in Phase II clinical trials. During his tenure at Flagship Pioneering, he helped found biotech companies and led programs focused on genetic diseases at Relay Therapeutics. At Curie.Bio, he is dedicated to ensuring that founders have the expertise and support they need.